Overview

* Perrigo Q3 2025 net sales down 4.1%, missing analyst expectations

* Adjusted EPS for Q3 2025 beats analyst estimates

* Company updates FY 2025 outlook due to industry dynamics and market trends

Outlook

* Perrigo ( PRGO ) revises 2025 outlook due to infant formula dynamics and soft OTC trends

* Company expects 2025 adjusted EPS of $2.70 to $2.80, up 5% to 9%

* Perrigo ( PRGO ) forecasts 2025 net sales growth of -2.5% to -3.0%

Result Drivers

* OTC MARKET SHARE GAINS - Perrigo ( PRGO ) achieved dollar, unit, and volume share gains in five of seven OTC store brand categories despite soft market consumption trends

* STRATEGIC BUSINESS REVIEWS - Ongoing strategic reviews of Infant Formula and Oral Care businesses, with a focus on portfolio evaluation

* CURRENCY AND COST MANAGEMENT - Favorable currency translation and disciplined cost management partially offset declines in adjusted operating income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Miss $1.04 $1.09

bln bln (3

Analysts

)

Q3 Beat $0.80 $0.75 (3

Adjusted Analysts

EPS )

Q3 EPS $0.09

Q3 Beat $173 mln $168.60

Adjusted mln (3

Operatin Analysts

g Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Perrigo Company PLC ( PRGO ) is $32.00, about 36.9% above its November 4 closing price of $20.19

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)